The sessions may be accessed from the "Investors & Media" page of Regeneron's website at https://investor.regeneron.com/events-and-presentations. Replays and ...
Wolfe Research analyst Alexandria Hammond initiated coverage of Regeneron (REGN) with an Outperform rating and $1,150 price target Published first on TheFly – the ultimate source for real-time ...
Also Read: Regeneron’s Dupixent COPD Sales To Reach $20B By 2026, Analyst Sees Larger Addressable Market The condition impacts millions globally, with a 2023 analysis by DelveInsight reporting ...
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) stock has reached its 52-week low, trading at $785.31. This price level reflects a subtle yet notable decline of 0.43% over the past year, indicating a ...
TARRYTOWN, N.Y., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: • Jefferies London Healthcare Conference at 11 ...
Regeneron Pharmaceuticals and Sanofi said the U.S. Food and Drug Administration has accepted their resubmitted application seeking expanded approval of the blockbuster anti-inflammatory drug ...
Regeneron (NASDAQ:REGN) Pharmaceuticals, Inc. (NASDAQ:REGN), a leading biotechnology company, finds itself at a critical juncture as it navigates challenges to its flagship product while ...
Shares of Regeneron Pharmaceuticals Inc. REGN slid 2.71% to $782.51 Thursday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index SPX falling 0.60% ...
Regeneron Pharmaceuticals (NASDAQ:REGN) underwent analysis by 28 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The following table provides a quick ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback